193 related articles for article (PubMed ID: 36517738)
1. A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study.
Hirano S; Kojima A; Nakayama Y; Takeda T; Kishimoto T; Takahashi T; Kuwabara S; Mori M
BMC Neurol; 2022 Dec; 22(1):483. PubMed ID: 36517738
[TBL] [Abstract][Full Text] [Related]
2. Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma.
Pedrero Prieto M; Gorriz Romero D; Gómez Roch E; Pérez Miralles FC; Casanova Estruch B
Neurol Sci; 2024 May; 45(5):2199-2202. PubMed ID: 38091210
[TBL] [Abstract][Full Text] [Related]
3. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
[TBL] [Abstract][Full Text] [Related]
4. Neuromyelitis optica spectrum disorder after treatment with pembrolizumab.
Shimada T; Hoshino Y; Tsunemi T; Hattori A; Nakagawa E; Yokoyama K; Hattori N
Mult Scler Relat Disord; 2020 Jan; 37():101447. PubMed ID: 31655267
[TBL] [Abstract][Full Text] [Related]
5. Neuromyelitis optica spectrum disorders in South of Tunisia: A rare entity with low seroprevalence of anti-aquaporin 4 autoantibodies.
Mejdoub S; Feki S; Dammak M; Farhat N; Hdiji O; Boukthir S; Hachicha H; Mhiri C; Masmoudi H
Rev Neurol (Paris); 2020 May; 176(4):261-267. PubMed ID: 31668529
[TBL] [Abstract][Full Text] [Related]
6. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report.
Narumi Y; Yoshida R; Minami Y; Yamamoto Y; Takeguchi S; Kano K; Takahashi K; Saito T; Sawada J; Terui H; Katayama T; Sasaki T; Ohsaki Y
BMC Cancer; 2018 Jan; 18(1):95. PubMed ID: 29361915
[TBL] [Abstract][Full Text] [Related]
7. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
8. Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort.
Castro-Suarez S; Guevara-Silva E; Osorio-Marcatinco V; Alvarez-Toledo K; Meza-Vega M; Caparó-Zamalloa C
Mult Scler Relat Disord; 2022 Aug; 64():103919. PubMed ID: 35691236
[TBL] [Abstract][Full Text] [Related]
9. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
[TBL] [Abstract][Full Text] [Related]
10. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
11. The relationship between aquaporin-4 antibody status and visual tract integrity in neuromyelitis optica spectrum disorders: A visual evoked potential study.
Barć K; Gospodarczyk-Szot K; Nojszewska M; Podlecka-Piętowska A; Zakrzewska-Pniewska B
Mult Scler Relat Disord; 2020 Sep; 44():102265. PubMed ID: 32575026
[TBL] [Abstract][Full Text] [Related]
12. Investigating paraneoplastic aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder through a data-driven approach.
Dinoto A; Borin GU; Campana G; Carta S; Ferrari S; Mariotto S
Eur J Neurol; 2022 Nov; 29(11):3466-3472. PubMed ID: 35767391
[TBL] [Abstract][Full Text] [Related]
13. Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.
Cotzomi E; Stathopoulos P; Lee CS; Ritchie AM; Soltys JN; Delmotte FR; Oe T; Sng J; Jiang R; Ma AK; Vander Heiden JA; Kleinstein SH; Levy M; Bennett JL; Meffre E; O'Connor KC
Brain; 2019 Jun; 142(6):1598-1615. PubMed ID: 31056665
[TBL] [Abstract][Full Text] [Related]
14. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies.
Sepúlveda M; Sola-Valls N; Escudero D; Rojc B; Barón M; Hernández-Echebarría L; Gómez B; Dalmau J; Saiz A; Graus F
Mult Scler; 2018 Nov; 24(13):1753-1759. PubMed ID: 28920766
[TBL] [Abstract][Full Text] [Related]
15. Clinical features of organizing pneumonia in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders.
Furube A; Kadota T; Gochi M; Saito S; Shibata S; Inaki S; Tone K; Takagi M; Matsuno H; Araya J; Yaguchi H; Kuwano K
Respir Investig; 2022 Sep; 60(5):684-693. PubMed ID: 35871065
[TBL] [Abstract][Full Text] [Related]
16. AQP4-IgG-positive neuromyelitis optica spectrum disorder and temporally detected neoplasms: case report and systematic review.
Apiraksattayakul N; Songwisit S; Owattanapanich W; Tisavipat N; Siritho S; Prayoonwiwat N; Rattanathamsakul N; Jitprapaikulsan J
Mult Scler Relat Disord; 2022 Dec; 68():104212. PubMed ID: 36242805
[TBL] [Abstract][Full Text] [Related]
17. Neuromyelitis optica, aquaporin-4 antibodies, and neuroendocrine disorders.
Iorio R; Papi C
Handb Clin Neurol; 2021; 181():173-186. PubMed ID: 34238456
[TBL] [Abstract][Full Text] [Related]
18. Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4.
Iorio R; Rindi G; Erra C; Damato V; Ferilli M; Sabatelli M
Mult Scler; 2015 May; 21(6):791-4. PubMed ID: 25716881
[TBL] [Abstract][Full Text] [Related]
19. Radiologically isolated aquaporin-4 antibody neuromyelitis optica spectrum disorder.
Abdel-Mannan O; Klein A; Bachar Zipori A; Ben-Sira L; Fattal-Valevski A; Hacohen Y; Meirson H
Mult Scler; 2022 Apr; 28(4):676-679. PubMed ID: 35332817
[TBL] [Abstract][Full Text] [Related]
20. AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature.
Spiezia AL; Carotenuto A; Iovino A; Moccia M; Gastaldi M; Iodice R; Tedeschi E; Petracca M; Lavorgna L; d'Ambrosio A; Brescia Morra V; Lanzillo R
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]